Plexium is the premier, next-generation targeted protein degradation company, seeking to discover a wide range of monovalent target protein degraders that address the limitations of PROTACs and cereblon. The company’s platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation.  From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases.

Join TechBio Companies Driving Patient Impact